| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Stroke | 26 | 2020 | 1128 | 3.360 |
Why?
|
| Brain Ischemia | 15 | 2020 | 399 | 2.680 |
Why?
|
| Leukoaraiosis | 6 | 2019 | 45 | 1.280 |
Why?
|
| Thrombolytic Therapy | 8 | 2020 | 184 | 1.270 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 5 | 2012 | 208 | 0.870 |
Why?
|
| Purpura, Thrombotic Thrombocytopenic | 1 | 2022 | 8 | 0.780 |
Why?
|
| Tissue Plasminogen Activator | 5 | 2020 | 125 | 0.750 |
Why?
|
| Fibrinolytic Agents | 3 | 2020 | 163 | 0.660 |
Why?
|
| Amyloid beta-Peptides | 3 | 2015 | 287 | 0.660 |
Why?
|
| Quality of Health Care | 2 | 2014 | 514 | 0.640 |
Why?
|
| Sleep | 2 | 2015 | 215 | 0.620 |
Why?
|
| Atrial Fibrillation | 4 | 2020 | 805 | 0.600 |
Why?
|
| Amnesia | 2 | 2015 | 9 | 0.580 |
Why?
|
| Anticoagulants | 4 | 2019 | 480 | 0.580 |
Why?
|
| Cerebral Infarction | 3 | 2015 | 76 | 0.480 |
Why?
|
| Health Status Disparities | 1 | 2016 | 137 | 0.470 |
Why?
|
| Humans | 57 | 2024 | 59440 | 0.460 |
Why?
|
| Heparin, Low-Molecular-Weight | 2 | 2006 | 26 | 0.450 |
Why?
|
| Platelet Aggregation Inhibitors | 2 | 2007 | 211 | 0.440 |
Why?
|
| Heparin | 2 | 2006 | 111 | 0.430 |
Why?
|
| Blood Pressure | 1 | 2015 | 496 | 0.420 |
Why?
|
| Aspergillosis | 4 | 1994 | 40 | 0.410 |
Why?
|
| Aged | 26 | 2020 | 13426 | 0.390 |
Why?
|
| Neuroimaging | 2 | 2014 | 144 | 0.380 |
Why?
|
| Arterial Occlusive Diseases | 1 | 2012 | 72 | 0.380 |
Why?
|
| Cognitive Dysfunction | 1 | 2015 | 309 | 0.370 |
Why?
|
| Male | 36 | 2020 | 27775 | 0.370 |
Why?
|
| Sex Characteristics | 1 | 2012 | 197 | 0.360 |
Why?
|
| Ischemic Attack, Transient | 2 | 2019 | 90 | 0.350 |
Why?
|
| Severity of Illness Index | 8 | 2019 | 1482 | 0.350 |
Why?
|
| Hypoglossal Nerve Diseases | 1 | 2009 | 2 | 0.340 |
Why?
|
| Dysarthria | 1 | 2009 | 7 | 0.340 |
Why?
|
| Internal Capsule | 1 | 2009 | 11 | 0.340 |
Why?
|
| Middle Aged | 23 | 2020 | 16335 | 0.340 |
Why?
|
| Tongue | 1 | 2009 | 15 | 0.330 |
Why?
|
| Movement Disorders | 1 | 2009 | 22 | 0.330 |
Why?
|
| Acute Disease | 6 | 2009 | 660 | 0.330 |
Why?
|
| Hospitalization | 1 | 2016 | 1293 | 0.310 |
Why?
|
| Female | 30 | 2020 | 30757 | 0.310 |
Why?
|
| Aspirin | 2 | 2007 | 167 | 0.310 |
Why?
|
| Telemedicine | 2 | 2014 | 310 | 0.300 |
Why?
|
| Heart Failure | 1 | 2016 | 853 | 0.300 |
Why?
|
| Predictive Value of Tests | 6 | 2020 | 1028 | 0.300 |
Why?
|
| Hypertension | 3 | 2016 | 570 | 0.300 |
Why?
|
| Magnetic Resonance Imaging | 7 | 2024 | 2053 | 0.300 |
Why?
|
| Tomography, X-Ray Computed | 6 | 2014 | 1512 | 0.290 |
Why?
|
| Aged, 80 and over | 12 | 2020 | 5129 | 0.280 |
Why?
|
| Alzheimer Disease | 5 | 2009 | 681 | 0.270 |
Why?
|
| Coronary Angiography | 1 | 2007 | 176 | 0.270 |
Why?
|
| White Matter | 2 | 2019 | 114 | 0.270 |
Why?
|
| Brain | 4 | 2017 | 1488 | 0.260 |
Why?
|
| Risk Factors | 8 | 2020 | 4990 | 0.260 |
Why?
|
| Cerebrovascular Circulation | 2 | 2012 | 174 | 0.260 |
Why?
|
| Diagnosis, Computer-Assisted | 1 | 2006 | 43 | 0.250 |
Why?
|
| Polysomnography | 1 | 2006 | 55 | 0.250 |
Why?
|
| Cardiac Catheterization | 1 | 2007 | 253 | 0.250 |
Why?
|
| Cerebral Hemorrhage | 5 | 2017 | 85 | 0.250 |
Why?
|
| Cognition Disorders | 2 | 2005 | 215 | 0.250 |
Why?
|
| Sleep Wake Disorders | 1 | 2006 | 65 | 0.240 |
Why?
|
| Encephalomyelitis, Eastern Equine | 1 | 2024 | 2 | 0.240 |
Why?
|
| Treatment Outcome | 10 | 2020 | 5287 | 0.230 |
Why?
|
| Retrospective Studies | 12 | 2024 | 6081 | 0.230 |
Why?
|
| Peptide Fragments | 2 | 2007 | 401 | 0.230 |
Why?
|
| HIV-1 | 5 | 2001 | 692 | 0.220 |
Why?
|
| Presenilin-1 | 4 | 2009 | 59 | 0.220 |
Why?
|
| Ticlopidine | 1 | 2003 | 45 | 0.210 |
Why?
|
| Injections, Intravenous | 4 | 2009 | 155 | 0.210 |
Why?
|
| Antihypertensive Agents | 1 | 2004 | 163 | 0.210 |
Why?
|
| Disintegrins | 1 | 2022 | 4 | 0.200 |
Why?
|
| ADAMTS13 Protein | 1 | 2022 | 6 | 0.200 |
Why?
|
| Thrombospondins | 1 | 2022 | 6 | 0.200 |
Why?
|
| Antifungal Agents | 2 | 1993 | 120 | 0.190 |
Why?
|
| Cholesterol | 3 | 2009 | 253 | 0.190 |
Why?
|
| Receptors, CXCR4 | 1 | 2001 | 34 | 0.190 |
Why?
|
| Th2 Cells | 1 | 2001 | 99 | 0.180 |
Why?
|
| Receptors, CCR5 | 1 | 2001 | 56 | 0.180 |
Why?
|
| Models, Biological | 1 | 2006 | 1143 | 0.180 |
Why?
|
| Algorithms | 1 | 2006 | 978 | 0.180 |
Why?
|
| Incidence | 2 | 2019 | 1239 | 0.180 |
Why?
|
| Th1 Cells | 1 | 2001 | 174 | 0.180 |
Why?
|
| Hematoma | 2 | 2019 | 68 | 0.170 |
Why?
|
| Time Factors | 6 | 2019 | 3621 | 0.170 |
Why?
|
| Bed Rest | 1 | 2019 | 10 | 0.170 |
Why?
|
| Vitamin K | 1 | 2019 | 14 | 0.160 |
Why?
|
| Secondary Prevention | 3 | 2006 | 151 | 0.160 |
Why?
|
| Intracranial Hemorrhages | 1 | 2019 | 61 | 0.160 |
Why?
|
| Mechanical Thrombolysis | 1 | 2019 | 35 | 0.160 |
Why?
|
| Leukoencephalopathies | 1 | 2019 | 24 | 0.150 |
Why?
|
| Heterozygote | 3 | 2009 | 162 | 0.150 |
Why?
|
| Dementia | 2 | 2003 | 248 | 0.140 |
Why?
|
| Neuropsychological Tests | 2 | 1996 | 372 | 0.140 |
Why?
|
| Prevalence | 3 | 2020 | 1257 | 0.140 |
Why?
|
| Recombinant Proteins | 3 | 2020 | 691 | 0.130 |
Why?
|
| Occipital Lobe | 1 | 1996 | 17 | 0.130 |
Why?
|
| Eligibility Determination | 1 | 2016 | 35 | 0.130 |
Why?
|
| India | 2 | 2014 | 150 | 0.130 |
Why?
|
| California | 1 | 2016 | 161 | 0.130 |
Why?
|
| Meningeal Neoplasms | 1 | 1996 | 58 | 0.130 |
Why?
|
| Cerebrum | 1 | 2015 | 16 | 0.130 |
Why?
|
| Time-to-Treatment | 1 | 2016 | 98 | 0.120 |
Why?
|
| Glioblastoma | 2 | 1998 | 155 | 0.120 |
Why?
|
| Endovascular Procedures | 3 | 2017 | 609 | 0.120 |
Why?
|
| National Institutes of Health (U.S.) | 1 | 2015 | 111 | 0.120 |
Why?
|
| Survival Analysis | 2 | 2007 | 554 | 0.120 |
Why?
|
| Clodronic Acid | 1 | 1994 | 4 | 0.110 |
Why?
|
| Amphotericin B | 1 | 1994 | 21 | 0.110 |
Why?
|
| Risk Assessment | 4 | 2020 | 1926 | 0.110 |
Why?
|
| Brain Neoplasms | 2 | 1998 | 302 | 0.110 |
Why?
|
| Phagocytes | 1 | 1994 | 50 | 0.110 |
Why?
|
| Patient Selection | 1 | 2016 | 465 | 0.110 |
Why?
|
| Multivariate Analysis | 3 | 2017 | 903 | 0.110 |
Why?
|
| Prognosis | 3 | 2009 | 1597 | 0.110 |
Why?
|
| Length of Stay | 1 | 2017 | 779 | 0.110 |
Why?
|
| Lethal Dose 50 | 4 | 1994 | 14 | 0.110 |
Why?
|
| Phosphatidic Acids | 1 | 1993 | 7 | 0.110 |
Why?
|
| Infarction, Middle Cerebral Artery | 1 | 2014 | 70 | 0.100 |
Why?
|
| Recurrence | 2 | 2005 | 603 | 0.100 |
Why?
|
| Mannose | 1 | 1993 | 21 | 0.100 |
Why?
|
| Cognition | 1 | 1996 | 454 | 0.100 |
Why?
|
| Aspergillus fumigatus | 1 | 1993 | 52 | 0.100 |
Why?
|
| Liposomes | 4 | 1994 | 100 | 0.100 |
Why?
|
| Diffusion Magnetic Resonance Imaging | 2 | 2020 | 145 | 0.100 |
Why?
|
| Tetanus | 1 | 1991 | 5 | 0.100 |
Why?
|
| Mutation | 4 | 2009 | 2458 | 0.090 |
Why?
|
| Diagnosis, Differential | 3 | 2019 | 933 | 0.090 |
Why?
|
| Spinal Cord Compression | 1 | 1991 | 28 | 0.090 |
Why?
|
| Macrophage Activation | 1 | 1992 | 118 | 0.090 |
Why?
|
| Diabetes Mellitus | 1 | 2016 | 515 | 0.090 |
Why?
|
| Cohort Studies | 2 | 2019 | 2376 | 0.090 |
Why?
|
| Mice, Inbred BALB C | 4 | 1994 | 868 | 0.090 |
Why?
|
| Follow-Up Studies | 2 | 2007 | 2339 | 0.090 |
Why?
|
| Phagocytosis | 1 | 1992 | 260 | 0.090 |
Why?
|
| Randomized Controlled Trials as Topic | 2 | 2004 | 678 | 0.090 |
Why?
|
| Delivery of Health Care | 1 | 2014 | 413 | 0.090 |
Why?
|
| Efferent Pathways | 1 | 2009 | 13 | 0.080 |
Why?
|
| Transcranial Magnetic Stimulation | 1 | 2009 | 26 | 0.080 |
Why?
|
| Edema | 1 | 1989 | 42 | 0.080 |
Why?
|
| Peripheral Nerves | 1 | 1989 | 30 | 0.080 |
Why?
|
| Sensitivity and Specificity | 2 | 2017 | 1097 | 0.080 |
Why?
|
| Adult | 9 | 2019 | 15695 | 0.080 |
Why?
|
| Patient Education as Topic | 1 | 2013 | 453 | 0.080 |
Why?
|
| Macrophages | 2 | 1993 | 1015 | 0.080 |
Why?
|
| Eye | 1 | 1989 | 52 | 0.080 |
Why?
|
| Regression Analysis | 2 | 2014 | 487 | 0.080 |
Why?
|
| Hand | 1 | 2009 | 69 | 0.080 |
Why?
|
| Injections, Intra-Arterial | 1 | 2009 | 20 | 0.080 |
Why?
|
| Odds Ratio | 2 | 2016 | 747 | 0.080 |
Why?
|
| Plant Oils | 1 | 1989 | 56 | 0.080 |
Why?
|
| Emergency Service, Hospital | 1 | 2017 | 1022 | 0.080 |
Why?
|
| Polyenes | 3 | 1993 | 4 | 0.080 |
Why?
|
| Muscles | 1 | 1989 | 173 | 0.080 |
Why?
|
| Hyperparathyroidism | 1 | 1988 | 7 | 0.080 |
Why?
|
| Virus Replication | 3 | 2001 | 305 | 0.080 |
Why?
|
| Reproducibility of Results | 2 | 2019 | 1560 | 0.080 |
Why?
|
| Thalamic Diseases | 1 | 1988 | 2 | 0.070 |
Why?
|
| Clinical Competence | 1 | 2013 | 683 | 0.070 |
Why?
|
| Antiviral Agents | 3 | 1996 | 313 | 0.070 |
Why?
|
| Muscular Diseases | 1 | 1988 | 46 | 0.070 |
Why?
|
| Tissue Distribution | 3 | 1993 | 287 | 0.070 |
Why?
|
| Electroencephalography | 2 | 2024 | 135 | 0.070 |
Why?
|
| Animals | 8 | 2005 | 19661 | 0.070 |
Why?
|
| Platelet Function Tests | 1 | 2007 | 10 | 0.070 |
Why?
|
| Cyclooxygenase 1 | 1 | 2007 | 18 | 0.070 |
Why?
|
| Thromboxane A2 | 1 | 2007 | 5 | 0.070 |
Why?
|
| Platelet Activation | 1 | 2007 | 26 | 0.070 |
Why?
|
| Disease Progression | 2 | 2017 | 1119 | 0.070 |
Why?
|
| Amyloid beta-Protein Precursor | 1 | 2007 | 78 | 0.070 |
Why?
|
| Drug Resistance | 1 | 2007 | 95 | 0.070 |
Why?
|
| Pedigree | 1 | 2007 | 183 | 0.070 |
Why?
|
| Radiopharmaceuticals | 1 | 2007 | 181 | 0.070 |
Why?
|
| Amyloid | 1 | 2007 | 65 | 0.070 |
Why?
|
| Corpus Striatum | 1 | 2007 | 93 | 0.070 |
Why?
|
| Drug Administration Schedule | 2 | 2004 | 284 | 0.070 |
Why?
|
| Pattern Recognition, Automated | 1 | 2006 | 52 | 0.060 |
Why?
|
| Intracranial Thrombosis | 1 | 2006 | 27 | 0.060 |
Why?
|
| Information Storage and Retrieval | 1 | 2006 | 60 | 0.060 |
Why?
|
| Cerebral Angiography | 2 | 2014 | 280 | 0.060 |
Why?
|
| Cluster Analysis | 1 | 2006 | 245 | 0.060 |
Why?
|
| Ischemia | 1 | 2007 | 199 | 0.060 |
Why?
|
| Enzyme Inhibitors | 1 | 2007 | 347 | 0.060 |
Why?
|
| Drug Combinations | 2 | 2003 | 147 | 0.060 |
Why?
|
| Data Interpretation, Statistical | 1 | 2006 | 191 | 0.060 |
Why?
|
| Streptokinase | 1 | 2005 | 6 | 0.060 |
Why?
|
| Thrombosis | 1 | 2007 | 183 | 0.060 |
Why?
|
| Drug Therapy, Combination | 2 | 2005 | 451 | 0.060 |
Why?
|
| Expert Testimony | 1 | 2005 | 17 | 0.060 |
Why?
|
| Platelet Glycoprotein GPIIb-IIIa Complex | 1 | 2005 | 23 | 0.060 |
Why?
|
| Encephalitis Virus, Eastern Equine | 1 | 2024 | 1 | 0.060 |
Why?
|
| Family Health | 1 | 2005 | 67 | 0.060 |
Why?
|
| Recovery of Function | 2 | 2019 | 271 | 0.060 |
Why?
|
| Heart Diseases | 1 | 2007 | 206 | 0.060 |
Why?
|
| Venous Thrombosis | 1 | 2006 | 111 | 0.060 |
Why?
|
| DNA Mutational Analysis | 1 | 2005 | 188 | 0.060 |
Why?
|
| Meta-Analysis as Topic | 1 | 2005 | 77 | 0.060 |
Why?
|
| Models, Statistical | 1 | 2006 | 299 | 0.060 |
Why?
|
| Cerebrovascular Disorders | 1 | 2005 | 74 | 0.060 |
Why?
|
| Coronary Artery Disease | 1 | 2007 | 274 | 0.060 |
Why?
|
| Genetic Testing | 1 | 2005 | 126 | 0.060 |
Why?
|
| Neuroprotective Agents | 1 | 2005 | 72 | 0.060 |
Why?
|
| Risk | 1 | 2005 | 364 | 0.060 |
Why?
|
| Anticonvulsants | 1 | 2024 | 88 | 0.060 |
Why?
|
| Down-Regulation | 1 | 2005 | 307 | 0.060 |
Why?
|
| tau Proteins | 1 | 2005 | 191 | 0.060 |
Why?
|
| Aspirin, Dipyridamole Drug Combination | 1 | 2003 | 3 | 0.060 |
Why?
|
| Dipyridamole | 1 | 2003 | 17 | 0.050 |
Why?
|
| Artificial Intelligence | 1 | 2006 | 154 | 0.050 |
Why?
|
| Computer Simulation | 1 | 2006 | 459 | 0.050 |
Why?
|
| Primary Prevention | 1 | 2004 | 134 | 0.050 |
Why?
|
| Diagnostic Errors | 2 | 1996 | 94 | 0.050 |
Why?
|
| Logistic Models | 2 | 2017 | 1235 | 0.050 |
Why?
|
| Databases, Factual | 1 | 2006 | 814 | 0.050 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2004 | 805 | 0.050 |
Why?
|
| Health Services | 1 | 2003 | 81 | 0.050 |
Why?
|
| Chromatography, High Pressure Liquid | 2 | 1993 | 226 | 0.050 |
Why?
|
| Chemokines, CC | 1 | 2001 | 30 | 0.050 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2005 | 676 | 0.050 |
Why?
|
| Cell Polarity | 1 | 2001 | 110 | 0.050 |
Why?
|
| Drug Carriers | 2 | 1993 | 175 | 0.040 |
Why?
|
| DNA, Viral | 1 | 2001 | 223 | 0.040 |
Why?
|
| HIV Infections | 2 | 2000 | 913 | 0.040 |
Why?
|
| Electromyography | 2 | 1991 | 88 | 0.040 |
Why?
|
| Infusions, Intravenous | 1 | 2020 | 163 | 0.040 |
Why?
|
| Membrane Proteins | 1 | 2005 | 850 | 0.040 |
Why?
|
| Mice | 4 | 1994 | 10300 | 0.040 |
Why?
|
| Cell Line | 2 | 2001 | 1984 | 0.040 |
Why?
|
| Neurologic Examination | 1 | 2019 | 52 | 0.040 |
Why?
|
| Hemiplegia | 1 | 1998 | 4 | 0.040 |
Why?
|
| CD4-Positive T-Lymphocytes | 2 | 2000 | 621 | 0.040 |
Why?
|
| Administration, Oral | 1 | 2019 | 355 | 0.040 |
Why?
|
| Radiography | 1 | 2019 | 517 | 0.040 |
Why?
|
| Influenza Vaccines | 1 | 1998 | 91 | 0.040 |
Why?
|
| Triage | 1 | 2017 | 111 | 0.030 |
Why?
|
| Dementia, Multi-Infarct | 1 | 1996 | 4 | 0.030 |
Why?
|
| Brain Abscess | 1 | 1996 | 7 | 0.030 |
Why?
|
| Child | 3 | 1991 | 4194 | 0.030 |
Why?
|
| Zalcitabine | 1 | 1996 | 2 | 0.030 |
Why?
|
| Stavudine | 1 | 1996 | 3 | 0.030 |
Why?
|
| Linear Models | 1 | 2017 | 403 | 0.030 |
Why?
|
| Naphthalenesulfonates | 1 | 1996 | 1 | 0.030 |
Why?
|
| Fatal Outcome | 1 | 1996 | 116 | 0.030 |
Why?
|
| Reverse Transcriptase Inhibitors | 1 | 1996 | 28 | 0.030 |
Why?
|
| RNA, Messenger | 1 | 2001 | 1469 | 0.030 |
Why?
|
| Evoked Potentials, Auditory | 1 | 1995 | 10 | 0.030 |
Why?
|
| Dementia, Vascular | 1 | 1995 | 7 | 0.030 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2000 | 648 | 0.030 |
Why?
|
| Disease Models, Animal | 2 | 1993 | 2051 | 0.030 |
Why?
|
| Patient Admission | 1 | 2017 | 184 | 0.030 |
Why?
|
| Chi-Square Distribution | 1 | 2016 | 409 | 0.030 |
Why?
|
| Patient Transfer | 1 | 2016 | 91 | 0.030 |
Why?
|
| CD4 Antigens | 1 | 1996 | 148 | 0.030 |
Why?
|
| Disability Evaluation | 1 | 2016 | 199 | 0.030 |
Why?
|
| HIV Envelope Protein gp120 | 1 | 1996 | 130 | 0.030 |
Why?
|
| Cost of Illness | 1 | 2015 | 156 | 0.030 |
Why?
|
| Massachusetts | 1 | 2020 | 2022 | 0.030 |
Why?
|
| Emergency Medical Services | 1 | 2017 | 259 | 0.030 |
Why?
|
| Virulence | 1 | 1994 | 188 | 0.030 |
Why?
|
| Intensive Care Units | 1 | 2017 | 430 | 0.030 |
Why?
|
| ROC Curve | 1 | 2014 | 268 | 0.030 |
Why?
|
| Colony Count, Microbial | 1 | 1993 | 57 | 0.030 |
Why?
|
| Registries | 1 | 2016 | 801 | 0.030 |
Why?
|
| Endocytosis | 1 | 1992 | 149 | 0.020 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 2014 | 651 | 0.020 |
Why?
|
| Paresthesia | 1 | 1989 | 5 | 0.020 |
Why?
|
| Neurons, Afferent | 1 | 1989 | 17 | 0.020 |
Why?
|
| Electroretinography | 1 | 1989 | 26 | 0.020 |
Why?
|
| Neural Conduction | 1 | 1989 | 29 | 0.020 |
Why?
|
| Electrophysiology | 1 | 1989 | 88 | 0.020 |
Why?
|
| Intraocular Pressure | 1 | 1989 | 59 | 0.020 |
Why?
|
| Cell Membrane | 1 | 1992 | 487 | 0.020 |
Why?
|
| Receptors, Cell Surface | 1 | 1992 | 428 | 0.020 |
Why?
|
| Hydroxycholesterols | 1 | 2009 | 9 | 0.020 |
Why?
|
| Heptanoic Acids | 1 | 2009 | 21 | 0.020 |
Why?
|
| Glaucoma | 1 | 1989 | 46 | 0.020 |
Why?
|
| Simvastatin | 1 | 2009 | 27 | 0.020 |
Why?
|
| Disease Outbreaks | 1 | 1989 | 103 | 0.020 |
Why?
|
| Pyrroles | 1 | 2009 | 47 | 0.020 |
Why?
|
| Apolipoproteins E | 1 | 2009 | 109 | 0.020 |
Why?
|
| Parathyroid Glands | 1 | 1988 | 8 | 0.020 |
Why?
|
| Motor Neurons | 1 | 1989 | 203 | 0.020 |
Why?
|
| United States | 2 | 2015 | 7430 | 0.020 |
Why?
|
| Apolipoprotein E4 | 1 | 2007 | 45 | 0.020 |
Why?
|
| Preoperative Care | 1 | 1988 | 180 | 0.020 |
Why?
|
| Vitamin D | 1 | 1988 | 132 | 0.020 |
Why?
|
| Papilledema | 1 | 1987 | 10 | 0.020 |
Why?
|
| Retinitis Pigmentosa | 1 | 1987 | 28 | 0.020 |
Why?
|
| Positron-Emission Tomography | 1 | 2007 | 200 | 0.020 |
Why?
|
| Pilot Projects | 1 | 2009 | 915 | 0.020 |
Why?
|
| Calcium | 1 | 1988 | 557 | 0.010 |
Why?
|
| Tennessee | 1 | 2003 | 16 | 0.010 |
Why?
|
| Viral Load | 1 | 2000 | 220 | 0.010 |
Why?
|
| Immunity, Cellular | 1 | 2000 | 171 | 0.010 |
Why?
|
| Adolescent | 1 | 1989 | 5844 | 0.010 |
Why?
|
| Anti-HIV Agents | 1 | 2000 | 153 | 0.010 |
Why?
|
| Encephalomyelitis | 1 | 1998 | 5 | 0.010 |
Why?
|
| Medicare | 1 | 2003 | 601 | 0.010 |
Why?
|
| Interferon-gamma | 1 | 2000 | 551 | 0.010 |
Why?
|
| Longitudinal Studies | 1 | 2000 | 1188 | 0.010 |
Why?
|
| Lamivudine | 1 | 1996 | 7 | 0.010 |
Why?
|
| HIV Reverse Transcriptase | 1 | 1996 | 10 | 0.010 |
Why?
|
| Macaca fascicularis | 1 | 1996 | 46 | 0.010 |
Why?
|
| Cell Line, Transformed | 1 | 1996 | 98 | 0.010 |
Why?
|
| Binding, Competitive | 1 | 1996 | 98 | 0.010 |
Why?
|
| RNA-Directed DNA Polymerase | 1 | 1996 | 34 | 0.010 |
Why?
|
| Drug Synergism | 1 | 1996 | 132 | 0.010 |
Why?
|
| HIV Seropositivity | 1 | 1996 | 82 | 0.010 |
Why?
|
| In Vitro Techniques | 1 | 1994 | 473 | 0.010 |
Why?
|
| Polymerase Chain Reaction | 1 | 1994 | 495 | 0.010 |
Why?
|
| Polymers | 1 | 1996 | 316 | 0.010 |
Why?
|
| Rats | 1 | 1996 | 1911 | 0.010 |
Why?
|
| Monocytes | 1 | 1994 | 345 | 0.010 |
Why?
|
| Protein Binding | 1 | 1996 | 1555 | 0.010 |
Why?
|
| Foot Deformities, Congenital | 1 | 1987 | 2 | 0.000 |
Why?
|
| Hand Deformities, Congenital | 1 | 1987 | 2 | 0.000 |
Why?
|
| Blindness | 1 | 1987 | 38 | 0.000 |
Why?
|
| Fluorescein Angiography | 1 | 1987 | 57 | 0.000 |
Why?
|
| Syndrome | 1 | 1987 | 170 | 0.000 |
Why?
|